Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Sunshine Biopharma Q3 2026 Results: Net Loss of $1.22M, Loss Widens

Sunshine Biopharma Inc. reported a net loss of $4.03 million for the nine months ended September 30, 2026, compared to a loss of $3.83 million in the prior year period. While revenues decreased slightly to $26.79 million, the company significantly strengthened its cash position to $14.62 million through public offerings and warrant exercises.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue9.49.4
Gross profit3.13.1
Profit before tax-1.3-1.0
Net income-1.2-0.9
EPS (diluted, $ a share)$-5.20$-38.80

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+0.3%
Gross margin32.8%
Operating margin-13.7%
Source

10-Q filed with the SEC, NASDAQ: SBFM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Sunshine Biopharma Inc.: key numbers

Share price
$2.60Close, Nov 16
Market cap
$2.14M
Shares outstanding
823.77KLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Sunshine Biopharma Inc.

All →
4:05 PM ET 8-K
Shareholder Meeting

Sunshine Biopharma Shareholder Meeting

The majority shareholder and CEO, Dr. Steve N. Slilaty, approved by written consent several matters related to a public offering that closed on October 9, 2026. These approvals include the issuance of common stock in excess of 20% of outstanding shares at a discount and adjustments to the exercise price and share count of Series D Warrants.

5:25 PM ET 8-K
Capital Raise

Sunshine Biopharma Capital Raise of $6M

Sunshine Biopharma Inc. closed a best efforts public offering of approximately 10.9 million units for gross proceeds of $6.0 million. Each unit, priced at $0.55, consists of one share of common stock (or a pre-funded warrant) and two Series D warrants. The company intends to use the net proceeds for general corporate purposes and working capital.

Value
$6M
Counterparty
Aegis Capital Corp.
4:06 PM ET 8-K
Reverse Stock Split

Sunshine Biopharma Reverse Stock Split

Sunshine Biopharma's majority shareholder, CEO Dr. Steve N. Slilaty, has approved a written consent authorizing the board to effect a reverse stock split at a ratio of up to 1-for-20. The board retains discretion over the final ratio and the timing of the split, which will become effective 20 days after a definitive information statement is mailed to stockholders.

9:09 AM ET 8-K
Other 8-K Filing

Sunshine Biopharma Other 8-K Filing

Sunshine Biopharma announced a reduction in the exercise price of its outstanding Series B Warrants to $1.2046. This adjustment was triggered by recent sales of common stock under the company's existing at-the-market (ATM) offering program. The price remains subject to further potential adjustments based on the terms of the warrants.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.